Abstract
Colon cancer is a leading cause of cancer related mortality. Until very recently the only existing options that medical oncologists had to treat metastatic colon cancer were a combination of chemotherapy, anti-EGFR and anti-angiogenic agents. We currently have the first proof that immune therapies could be an effective approach to battle colorectal cancers that carry a mismatch repair machinery deficient phenotype. It is expected that as our knowledge of the different mechanisms of immune-resistance grows, this therapeutic modality might soon be applicable to all patients. However, due to the continuous increase in the cost of oncological drugs, some treatment overheads may soon become prohibitive for many. In this review we will examine the current evidence related to this topic with the objective to provide the reader with concise but practical information about the potential role of immunotherapy in CRC.
Keywords: Colon cancer, lynch syndrome, microsatellite instability, PD-1 blockage, pembrolizumab.
Reviews on Recent Clinical Trials
Title:What is the Current Role of Immunotherapy for Colon Cancer?
Volume: 11 Issue: 2
Author(s): Fernando Galanternik, Gonzalo Recondo, Matías E. Valsecchi, Martín Greco, Gonzalo Recondo, Máximo de la Vega and E. Diaz Cantón
Affiliation:
Keywords: Colon cancer, lynch syndrome, microsatellite instability, PD-1 blockage, pembrolizumab.
Abstract: Colon cancer is a leading cause of cancer related mortality. Until very recently the only existing options that medical oncologists had to treat metastatic colon cancer were a combination of chemotherapy, anti-EGFR and anti-angiogenic agents. We currently have the first proof that immune therapies could be an effective approach to battle colorectal cancers that carry a mismatch repair machinery deficient phenotype. It is expected that as our knowledge of the different mechanisms of immune-resistance grows, this therapeutic modality might soon be applicable to all patients. However, due to the continuous increase in the cost of oncological drugs, some treatment overheads may soon become prohibitive for many. In this review we will examine the current evidence related to this topic with the objective to provide the reader with concise but practical information about the potential role of immunotherapy in CRC.
Export Options
About this article
Cite this article as:
Galanternik Fernando, Recondo Gonzalo, E. Valsecchi Matías, Greco Martín, Recondo Gonzalo, de la Vega Máximo and Diaz Cantón E., What is the Current Role of Immunotherapy for Colon Cancer?, Reviews on Recent Clinical Trials 2016; 11 (2) . https://dx.doi.org/10.2174/1574887111666160330121851
DOI https://dx.doi.org/10.2174/1574887111666160330121851 |
Print ISSN 1574-8871 |
Publisher Name Bentham Science Publisher |
Online ISSN 1876-1038 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Emerging Role of Stromal Fibroblasts in Epithelial Cancer
Current Signal Transduction Therapy Insights into a Critical Role of the FOXO3a-FOXM1 Axis in DNA Damage Response and Genotoxic Drug Resistance
Current Drug Targets Epigenetic Therapies of Cancer
Current Cancer Therapy Reviews Proline-Directed Protein Kinase FA as a Potential Target for Diagnosis and Therapy of Human Cancers
Current Cancer Drug Targets Long Non-Coding RNA: An Emerging Paradigm of Pancreatic Cancer
Current Molecular Medicine Potential Novel Treatments for Bipolar Depression: Ketamine, Fatty Acids, Anti-inflammatory Agents, and Probiotics
CNS & Neurological Disorders - Drug Targets Consumption of Cooked Navy Bean Powders Modulate the Canine Fecal and Urine Metabolome
Current Metabolomics Nanosponges Encapsulated Phytochemicals for Targeting Cancer: A Review
Current Drug Targets Heat Shock Proteins as Prognostic Markers of Cancer
Current Cancer Drug Targets Fluorescent Porphyrin with an Increased Uptake in Peripheral Blood Cell Subpopulations from Colon Cancer Patients
Medicinal Chemistry Advances in Nanomaterials for Diagnosis and Therapy of Leukemia
Recent Patents on Nanomedicine New Cathepsin D Inhibitor Library Utilizing Hydroxyethyl Isosteres with Cyclic Tertiary Amines
Medicinal Chemistry A Review on Theragnostic Applications of Micrornas and Long Non- Coding RNAs in Colorectal Cancer
Current Topics in Medicinal Chemistry Editorial [Hot topic: New and Emerging Drug Targets for the Treatment of Hematological Malignancies (Guest Editors: Dr. Linda J. Bendall)]
Current Drug Targets Role of Human and Mouse HspB1 in Metastasis
Current Molecular Medicine Mucosal Healing in Crohn’s Disease: Relevance for Clinical Outcomes
Current Drug Targets Biological Ageing, Inflammation and Nutrition: How Might They Impact on Systemic Sclerosis?
Current Aging Science Small and Long Non-Coding RNAs: Novel Targets in Perspective Cancer Therapy
Current Genomics ATP-Binding Cassette Efflux Transporters in Human Placenta
Current Pharmaceutical Biotechnology Literature Evidence and ARRIVE Assessment on Neuroprotective Effects of Flavonols in Neurodegenerative Diseases' Models
CNS & Neurological Disorders - Drug Targets